Hospira (NYSE:HSP) said today that it plans to shut down a plant in Clayton, N.C., where it makes generic injectable drugs, saying it will discontinue or transfer production of the compounds it makes there.

"This action results from extensive analysis of the plant, careful assessment of market needs for the products manufactured there, and available capacity within our operations network, and is part of the company’s ongoing optimization and modernization efforts," Hospira said.

The Lake Forest, Ill.-based company said it expects the closure to cost about $45 million pre-tax, including a $22 million non-cash impairment for the 4th quarter.

The remaining charges will come this year, according to a regulatory filing, including $15 million in severance costs and $8 million in other non-cash charges. The $45 million tab doesn’t include the cost of moving any production from the Clayton facility to other plants, Hospira said.

Last week the FDA lifted an import ban on another Hospira plant in Costa Rica.